Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease.
Life Sci
January 2025
Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India. Electronic address:
Parkinson's disease (PD) is a neurological condition and is characterized by both motor and non-motor symptoms. Early diagnosis is essential for effective therapy and management; nevertheless, present diagnostic methods are frequently insufficient and primarily rely on clinical symptoms that appear later in the disease. Neuropeptides, such as alpha-synuclein (α-syn), Substance P (SP), neurotensin (Nts), Neuropeptide Y (NPY), and somatostatin (SST), exhibit significant potential as biomarkers for the early identification of Parkinson's disease (PD).
View Article and Find Full Text PDFTargeted Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE Alters Joints Inflammation.
Clin Nucl Med
February 2025
Department of Radiology, Stony Brook University, Stony Brook, NY.
High and frequent expression of somatostatin receptors in differentiated neuroendocrine neoplasms has paved the way for receptor-based, targeted peptide receptor radionuclide therapy especially for nonoperable or metastatic disease. Besides tumors, radiation, in one form or another, has been tested to treat inflammatory disease as well, and this goes back to the early 1990s when the first case of pneumonia treated with radiation showed complete resolution. Currently, radiotracers help in not only in vivo inflammation detection, characterization, and staging but also, and more importantly, for selection of treatment in individual patients.
View Article and Find Full Text PDFInter- and intra-tumoral heterogeneity on [Ga]Ga-DOTA-TATE/[Ga]Ga-DOTA-TOC PET/CT predicts response to [Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients.
EJNMMI Rep
November 2024
Division of Nuclear Medicine, Department of Radiology-Room 3820-AJPP, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Background: Indices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [Lu]Lu-DOTA-TATE PRRT.
Methods: NET patients who underwent [Lu]Lu-DOTA-TATE therapy at the University of Iowa from August 2018 to February 2021 were retrospectively evaluated. Radiomic features on the pre-PRRT somatostatin receptor PET/CT were evaluated using a custom MIM Software® LesionID workflow.
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.
J Neuroendocrinol
November 2024
Department of Internal Medicine, Section of Endocrinology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Peptide receptor radionuclide therapy (PRRT) using [Lu-DOTA,Tyr]octreotate (Lu-DOTATATE) represents an established treatment modality for somatostatin receptor-positive, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NET) of grade 1 or 2. The studies have demonstrated that four cycles of PRRT with Lu-DOTATATE prolongs progression-free survival and preserves quality of life, in patients with grade 1 and 2 advanced GEP NET. Notably, first-line PRRT using Lu-DOTATATE in grade 2 and 3 GEP NET patients has also shown efficacy and safety.
View Article and Find Full Text PDFSomatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective.
Brain Pathol
January 2025
Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil.
Article Synopsis
- There are five subtypes of somatostatin receptors (SST1-5) that play roles in various tumors, with SST2 and SST5 being the most relevant for diagnosis and treatment.
- The article reviews the biological features of SST, emphasizing the immunohistochemical evaluation of SST2 and SST5 in growth hormone-secreting pituitary tumors as predictors of treatment response to somatostatin receptor ligands (SRL).
- There is a need for standardized immunohistochemical techniques and scoring systems for SST2 and SST5 to enhance treatment strategies for patients with somatotroph tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!